| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426306 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(6 years from now) | |
| US10206813 | GLAUKOS | Implants with controlled drug delivery features and methods of using same |
Oct, 2030
(6 years from now) | |
Idose Tr is owned by Glaukos.
Idose Tr contains Travoprost.
Idose Tr has a total of 2 drug patents out of which 0 drug patents have expired.
Idose Tr was authorised for market use on 13 December, 2023.
Idose Tr is available in implant;intracameral dosage forms.
The generics of Idose Tr are possible to be released after 17 October, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 13, 2026 |
Drugs and Companies using TRAVOPROST ingredient
Market Authorisation Date: 13 December, 2023
Treatment: NA
Dosage: IMPLANT;INTRACAMERAL
More Information on Dosage
IDOSE TR family patents
